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Abstract
It has long been established that a diet rich in fresh fruits, vegetables, seeds, grains and 
legumes and antioxidants, and other beneficial compounds may help prevent vari-
ous human diseases. However, diet is not a cure for treatment of severe diseases, but 
it may help prevent some ailments, and it can help the body overcome the effects of 
conventional treatments. Natural compounds not only serve as a drug or template for 
drugs but also, in many instances, had been a source of discovery of novel biology that 
provided better understanding of target and pathway involved in the disease processes. 
In addition, drugs derived from natural compounds work better for patients than do 
drugs manufactured synthetically. Approximately, 40% of drugs in the pipeline and 70% 
of synthetic therapeutic molecules are plagued with poor solubility, oral bioavailability, 
and delivery. Drugs with poor solubility encounter limited transport during oral admin-
istration because of low concentration gradient between the gut and the blood vessels. To 
increase body fluid saturation solubility of poorly soluble drug, new delivery methods 
need to be developed using natural dietary plant metabolites.
Keywords: plant metabolite, human ailments, disease therapy, nanomedicine
1. Introduction
1.1. Natural dietary products
Natural product therapeutic compound is a substance or compound produced by living organ-
isms which has pharmacological or biological activity and with potential to be developed into 
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new pharmaceuticals. Natural products may be extracted from plant tissues, marine organ-
isms or microorganism fermentation broths by various mechanical methods [1, 2].
The earliest records of natural products and oldest medical text come from ancient 
Mesopotamia corresponding to modern-day Iraq (2600 BC), which is written on hundreds of 
clay tablets in cuneiform. The tablets describe approximately 1000 plants and plant-derived 
substances, such as the oils of Cedrus species (cedar), resin of Commiphora myrrha (myrrh), and 
juice of the poppy seed Papaver somniferum with therapeutic potential [3]. The Chinese were 
the first to use medicinal plants from which over 11,000 herbal remedies were developed and 
used for thousands of years. In India, natural products are generally accepted as the main 
disease treatment method, as such almost 70% modern medicines in India are derived from 
natural products [2].
According to the recent WHO studies, over 30% of plant species of the world have been used 
for medicinal purposes. Among the estimated 250,000–500,000 higher plant species on earth, 
more than 80,000 species are purported to possess medicinal properties. However, only a 
small percentage of these plants has been investigated phytochemically [2]. Some natural 
compounds are already known to be useful drugs and these include alkaloids, morphine, 
and quinine, while others such as cocaine have been the basis for synthetic drug develop-
ment. Among the compound that has been isolated from plants in recent years include the 
anticancer agent paclitaxel (Taxol) from the yew tree and the antimalarial agent artemisinin 
from Artemisia annua [1].
1.2. Natural products as anticancer agents
It has long been known that a diet rich in fresh fruits, vegetables, seeds, grains, legumes and 
antioxidants, and other beneficial compounds may help prevent diseases. The evidences are 
compelling that healthy diet supplemented with vitamins, antioxidants or other beneficial 
micronutrients has real influence in reducing cancer incidence and mortalities. It was esti-
mated that one-third of all cancer cases could be prevented by a healthy diet [4, 5].
Although the search for natural compounds against cancers is still ongoing and exhaustive, 
more than 100 new products have already been developed for cancer therapy. However, the 
potential discovery of new cancer therapeutics is still enormous because approximately 80% 
of the rain forest plant species are likely to contain chemicals with anticancer properties, while 
only a fraction of these plants has been analyzed for their therapeutic properties [6].
There are several compounds from natural products that can directly or indirectly serve to treat can-
cers. The immune system can be boosted to recognize cancer cells through glutamine, melatonin, 
parthenolide, resveratrol (from red grape), carotenoids (pigments in vegetables), indole-3-carbinol, 
vitamin D, emodin, vitamin E, genistein (from red clover and soy products), proanthocyanides 
(from grape seed and pine bark), flavonoids (from tea family and berry family), and lycopene 
(from tomatoes) [7]. Other compounds proposed to have anticancer properties are garlic (Allium 
sativum), ginkgo (Ginkgo biloba), echinacea (Echinacea purpurea), ginseng (Panax ginseng), St John’s 
wort (Hypericum perforatum), ginger (Zingiber zerumbet), kava (Piper methysticum) [8] and cabbage, 
licorice, onions, flax, turmeric, cruciferous vegetables, peppers, brown rice, wheat, and the umbel-
liferous vegetables such as carrots, celery, and parsley [6].
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1.2.1. Zingiber
Ginger herb with white, red, or yellow flowers and dark green leaves and thick roots is a set of 
plants with various medicinal and culinary values found in many parts of the world including 
Malaysia. Ginger belongs to the genus Zingiber representing approximately 141 species under 
the family Zingiberaceae. The word ginger comes from the Latin Sanskrit word Sringavera, 
meaning that the rhizomes look like antlers of deer or horns of bull. The underground stems 
of ginger, which is the rhizomes, are knobby and fleshy, covered in ring-like scars and are 
used as food and medicine. Among the ginger, species with potential for high medicinal val-
ues are Zingiber officinale and Zingiber zerumbet [8, 9].
1.2.2. Zingiber zerumbet (L.) Smith
Zingiber zerumbet (L.) Smith (Figure 1) is an edible ginger, native to India and the Malay 
Peninsula, although it can be found in many countries including Indonesia, China, Bangladesh, 
Vietnam, Japan, Burma, Nepal, Sri Lanka, Jamaica, and Nigeria. This herbal plant is com-
monly known as the pinecone, wild ginger, Asian ginger or shampoo ginger. It is known by 
various names in different countries such as lempoyang in Malaysia and Indonesia, Ghatian 
and Yaiimu in India, Jangliadah in Bangladesh, Hong qui jiang in China, Haeo dam in Northern 
Thailand, Awapuhi in Hawaii, and zurunbah among the Arabians [8]. Generally, the rhizomes 
and leaves are used for spice, tea, beverages, and medical purposes, while the milky, muci-
laginous substance of the pinecones is used as shampoo and natural hair conditioner [9].
Zingiber zerumbet contains several types of phytochemicals and is considered as one of the 
widely used traditional dietary condiments for cuisines, food, and beverages throughout 
the Asia, and the essential oil is used as perfume and toilet article. In traditional orien-
tal medicine, the oil is used for a variety of digestive conditions [10]. The extract of the 
rhizome has been extensively studied for its antimicrobial, anticonvulsant, antipyretic, 
analgesic, antiulcer, antioxidant, antitumor, anticancer, antispasmodic, anti-inflammatory, 
antinociceptive, anticoagulant, antidiabetic, antihyperlipidemic and antiobesogenic, anti-
allergenic, anti-platelet aggregation, and hepatoprotective activities. Additional studies 
Figure 1. Zingiber zerumbet (A) tree and (B) inflorescence.
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had showed that rhizome consumption can lower blood cholesterol levels by reducing 
cholesterol absorption in the blood and liver, making this extract useful for treatment of 
heart diseases [11–13].
1.2.3. Ginger oil
Ginger oil is obtained from unpeeled or dried, ground-up root (rhizome) of Zingiber zerumbet 
by steam distillation. Ginger oil can vary in color from pale yellow to a dark amber, and the 
viscosity ranges from medium to watery. It has a strong spicy odor, sharp, warm and with a 
hint of lemon and pepper, and smells of actual ginger. The taste of ginger oil is peculiar and 
pungent [14].
1.2.4. Zerumbone
Zerumbone (ZER) was first isolated in 1960 from the essential volatile oil of rhizomes of Zingiber 
zerumbet, while its structure was first determined in 1965 and later characterized by NMR 
and X-ray. Zerumbone (Figure 2) is a sesquiterpene phytochemical compound isolated from 
Zingiber zerumbet (L.) smith or Zingiber aromaticum. It contains three double bonds, two conju-
gated and one isolated, as well as a conjugated carbonyl group in 11-membrane ring structure 
[16, 17]. Among parts of the plant richest in ZER are rhizomes followed by the leaves [18, 19]. 
Zerumbone is also the major compound (59%) in the essential oil from Zingiber zerumbet [20].
1.3. General medicinal properties of zerumbone
Several biological activities of ZER have been reported both in vivo and in vitro. These studies 
have found ZER to possess antitumor, anti-inflammatory, antioxidant, antimicrobial, antino-
ciceptive, antiatherosclerosis, hepatoprotective, antiplatelet aggregation, and immunomodu-
latory activities at different doses and concentrations [21].
Figure 2. Chemical structure of zerumbone [15].
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1.4. Carrier systems for drug delivery
Generally, the number of drugs and drug candidates is steadily increasing over the last 
2 decades. A number of these drugs have poor water solubility, which consequently 
cause poor oral bioavailability and delivery. Drug of poor bioavailability will not be read-
ily absorbed from the gastrointestinal tract into circulation and would not reach the site 
of action. However, solubilization of poorly soluble drugs is limited by drug properties, 
chemistry, molecular size, and selective solubility in certain organic media [22]. For sev-
eral year approaches to increase drug solubility by solubilization with surfactants, complex 
formation (cyclodextrins and macromolecules), microemulsions, and micronization of drug 
powders to increase the surface area and stability has not been very successful because the 
dissolution velocity of these drug was insufficient to overcome the lack of bioavailability to 
meet biopharmaceutical specification [23]. Therefore, there is a desperate need to develop 
innovative pharmaceutical carriers and delivery systems that overcome these drawbacks. 
Generally, carrier schemes for drug delivery should be toxicity-free, possess sufficient drug 
loading capacity, and have tissue targeting and controlled release characteristics. The carri-
ers should also afford chemical and physical stability to incorporated drug. To achieve their 
commercial potentials, these carrier and delivery systems should be feasible for production 
scaling-up at reasonable costs [24].
1.5. Colloidal carrier system
Colloidal drug carrier systems (Figure 3) have received great attention as potential drug 
delivery system because they offer many advantages as drug delivery vehicles including 
capability of increasing dissolution velocity that also increases bioavailability and solubility 
saturation. This can be achieved by reducing the size of the particle that increases surface 
area while increasing dissolution velocity. Thus, suitable nanoparticles can be employed as 
delivery systems with solid colloidal particle size ranging from 1 to 1000 nm [25].
Colloids consist of least two components; one dispersed in the other as fine particles in any 
state of matter. As pharmaceutical carriers, colloidal drug delivery systems can be classed 
into polymer systems (micelles, dendrimers, etc.), self-assembled lipid systems (liposomes, 
emulsions, SLN, NLC, etc.), drug nanoparticle systems, and pro-colloidal systems (self-
emulsifying oral delivery systems and liquid crystalline systems) [23]. Lipids are physiologi-
cally natural occurring compounds that are well tolerated, usually nontoxic or degradable 
to nontoxic residues. Thus, the lipid-based nanoparticles provide an advantage over other 
types of carrier systems. Liposomes and micelles are among the first colloidal drug carriers 
developed to overcome the possibilities of water-insoluble drug formulations [26]. They are 
naturally derived phospholipids and surfactant vesicles that can be filled with various drugs 
[27]. Liposomes and micelles are rapidly degradation by the pH of the stomach, intestinal 
enzymes, and bile salts after oral administration but have restricted physical and chemical 
stability during storage. These particles characteristically cause fast release of the drug while 
not so stable over extended period of storage. The liposomes and micelles also leave behind 
residues of the organic solvents and cause some degrees of toxicity to normal tissues. These 
characteristics make these colloidal carriers not optimal as a pharmaceutical carrier system.




Solid lipid nanoparticle (SLN) (Figure 4) is also a colloidal drug carrier system developed as an 
alternative system to the existing traditional carrier systems [28]. Although SLN have numer-
ous advantages including targeted drug delivery and increased stability of incorporated drug, 
they are still fraught with limitations. The matrix of SLN is highly ordered crystalline lipid 
structure leaving very little space for incorporation of drug molecules, thus limiting the load-
ing capacity. The net effect of these properties is expulsion of incorporated during storage. To 
overcome these limitations, a second generation lipid nanoparticle, the nanostructured lipid 
carrier (NLC) was introduced [29]. Nanostructured lipid carrier is a novel lipid nanoparticle, 
which in contrast to SLN consists of a mixture of solid and liquid lipids, in fine proportions. 
This formulation of NLC prevents the formation of perfect crystals and minimizes the drug 
expulsion phenomenon during storage [30]. With the introduction of NLC, lipid colloid carri-
ers began to gain new life as a potential drug carrier and delivery system [29].
In last couple of years, NLC has attracted great attention as an alternate carrier for the phar-
maceutical for anticancer drugs [24]. The NLC contains liquid lipids with different fatty acid 
C-chains responsible for producing the less-organized crystalline structure, providing better 
and higher drug loading capacity accommodation [31]. Several methods have been used to 
prepare the lipid nanoparticles of different size, surface characteristic, and stability. The prep-
aration of stable NLC of high surface area is based on three principles, namely precipitation, 
milling, and high pressure homogenization [22]. In the precipitation phase, the drug is dis-
solved in a solvent and subsequently added to a nanosolvent resulting in the precipitation of 
finely dispersed drug nanoparticles [25]. In the milling method, the dimension of particles is 
achieved by using different sizes of bead, ball mills or a pearl mill that consisting of ceramics, 
stainless steel, glass or highly cross linked polystyrene resin coated as milling media. The high 
pressure homogenization (HPH) generates small nanoparticle under pressure. Surfactants are 
required to stabilize the particle at the desired size. Lipid nanoparticles can also be produced 
by either hot or cold HPH technique. Other less common methods include spray drying, 
Figure 3. Various types of nanoparticles as drug delivery system. SLN—solid lipid nanoparticle and NLC—nanostructured 
lipid carrier. (http://www.pharmatutor.org/articles/nanotechnology-nanocrystal, 2013).
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ultrasonication, solvent evaporation, film ultrasound dispersion, microemulsion based, and 
supercritical fluid methods [25].
1.7. Nanostructured lipid carriers
Nanostructured lipid carriers are fine blends between solid and liquid lipids stabilized by the 
introduction of surfactants. Three different approaches have been developed to optimize the 
structure of NLC. First, imperfect type or type I NLC is prepared by blending spatially differ-
ent lipid types (solid and oil) to create distance between the fatty acid chains of the glycerides 
and imperfections in the crystal. This procedure offers more space for the accommodation of 
drug molecules and amorphous clusters of drugs, thus higher drug loading in the NLC. At the 
final stage, solid particles are produced by crystallization of liquid lipid particles (nanoemul-
sions) at room temperature from the cooled molten state. Basically, drug solubility is higher in 
liquid lipids than in solid lipids, and thus particles produced with high content of liquid lipids 
can load more drug [32]. Multiple type or type II NLC is prepared by mixing high liquid lipid, 
solid lipid, water, and drug. The high oil concentrations produce miscibility gap between solid 
lipids and liquid lipids during the cooling phase leading to phase separation and consequently 
precipitation of tiny oily nanocompartments. Finally, amorphous type or type III or multiple 
oil/fat/water type NLC is prepared by mixing solid lipids while in amorphous state. Solid lipid 
particle crystallization that can occur upon cooling is prevented by adding special lipids such 
as hydroxyoctacosanyl-hydroxystearate and isopropyl myristate [25, 32].
1.8. Characterization of nanostructured lipid carriers
Characterization of NLC is essential to determine the properties of the nanoparticle. Among 
the techniques employed to characterize nanoparticles include image analysis which includes 
light microscope, scanning electron microscope (SEM), transmission electron microscope 
(TEM), and atomic force microscope (AFM) to characterize and determine particle size and 
shape. Nuclear magnetic resonance (NMR) is used to determine particle size and qualitative 
nature of nanoparticle. Other characteristics of nanoparticles of concern are zeta potential (ZP), 
which characterizes ionization properties that dictates the agglomeration behavior of nanopar-
ticles. Polydispersity index (PDI) is a measure of distribution of molecular mass in a given 
Figure 4. Solid lipid nanoparticle and nanostructured lipid carriers. I—highly imperfect matrix, II—multiple oil/fat/
water type, and III—noncrystalline nanostructured nanoparticle [24].
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polymer sample. It is a measure of particle size distribution. The PDI values are always greater 
than 1; however, as the size becomes more uniform, the PDI approaches 1. The ZP, PDI, and 
particle can be determined using a Zetasizer. The efficiency of nanoparticles as a drug carrier 
system can be partially determined by the entrapment efficiency (EE) and drug loading (DL) 
capacity. Entrapment efficiency is the ratio of weight of drug entrapped in a carrier system 
to the total drug added, while DL is the ratio of drug to the weight of the total carrier sys-
tem. The EE and DL can be determined by high performance liquid chromatography (HPLC) 
technique, which at the same time can be used to determine the content of a substance and/
or its chemical stability. It is optimal for a drug delivery system to exhibit sustained release 
characteristics. This feature of drug-loaded nanoparticles can be analyzed using the Franz 
Diffusion Cell (FDC), which determines the rate of drug release from lipid particles. Thermal 
stability is another important feature of a drug carrier and nanoparticle delivery systems. This 
is essential because the preparation of these particles is done under high temperatures. The 
differential scanning calorimetry (DSC) is used to determine the physical and energetic prop-
erties of a substance as a function of temperature. The X-ray diffractometer was developed to 
measure the geometric scattering radiation from crystal planes within nanoparticle dispersion 
for assessing the degree of crystallinity using wide-angle X-ray diffraction (WXRD) [33, 34].
1.9. Nanoparticles in parenteral applications
In disease therapy, nanoparticles can be administered via several routes of administration, that 
is, parenteral, oral, intraocular, rectal, nasal, transdermal, or pulmonary inhalation [25, 35]. 
Thus, the understanding of the nature of targets and their interaction of the nanoparticles in 
a biological environment is imperative in the design of carrier systems [33]. Nanoparticles are 
large enough to be removed from circulation after intravenous injection by the macrophages 
through phagocytosis. Thus, this rapid removal of colloidal particles by the free circulating 
macrophages is a major obstacle of tissue targeting of drug-loaded nanoparticles. Similarly, 
fixed macrophages in tissue can also be phagocytose carrier drugs. Particles smaller than 7 μm 
are normally trapped in the small pulmonary vessels, while larger particles will pass through 
capillary beds of lungs to liver and spleen, which are then engulfed by the fixed macrophages. 
Consequently, these organs will be the primary deposition sites for small nanoparticles [32]. 
The size, surface properties of carrier, and the total amount of serum protein adsorbed on 
the surface of nanoparticle are the most important factors affecting the macrophage uptake 
process of drug carrier. The rate of clearance of the drug carriers is approximately propor-
tional to the amount of serum protein adsorbed on their surfaces. Hydrophobic particles will 
be removed from the circulation more rapidly than hydrophilic particles. Thus, to prolong 
circulation time, the drug carrier should be formulated with little to no serum adsorption. 
Currently, among the challenges is the design and formulation of colloidal carriers with pro-
longed distribution in the body is to find means to delay clearance from the body by avoiding 
the macrophages of the monocyte-phagocytic system [25].
1.10. Nanoparticles for cancer therapy
The development of nanotechnology is exponential and touted to be the technology that could 
revolutionize how drugs are delivered. Transfer of materials into the nanodimensions changes 
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their physical properties but not their biological activities, and this phenomenon is used in 
pharmaceutics to develop new innovative formulations for poorly soluble drugs [36]. The use 
of nanotechnology in cancer treatment offers some exciting possibilities, including tissue tar-
geting and destruction of cancerous cells and tumors with minimal toxicity to the healthy tis-
sue and organs. If well designed, the formulations may detect and eliminate cancer cells early 
before they form tumors [37]. The small size of nanoparticles endows them with properties 
that allow them to preferentially accumulate at tumor sites and when used in association with 
magnetic resonance imaging (MRI) can produce exceptional images of the tumors. Another 
property of nanoparticles is the high surface area to volume ratio that allows many functional 
groups to be attached, for example, groups that can seek out and bind to tumor cells [38].
2. Conclusion
Cancer nanotherapeutics is rapidly progressing and is being implemented to overcome limi-
tations of conventional drug delivery systems. Early clinical results suggest that nanoparticle 
therapeutics shows enhanced efficacy, while reducing side effects. The major role of nanopar-
ticle in drug delivery is to increase the dissolution velocity by reduction size and increasing 
surface area and bioavailability. Nanoparticle can carry loaded drugs to cancer cells selec-
tively through the unique pathophysiology of tumors, such as enhanced permeability and 
retention of drugs in the tumor microenvironment.
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